ATE497809T1 - Myricitrin verbindungen zur behandlung von schlafstörungen - Google Patents
Myricitrin verbindungen zur behandlung von schlafstörungenInfo
- Publication number
- ATE497809T1 ATE497809T1 AT05750345T AT05750345T ATE497809T1 AT E497809 T1 ATE497809 T1 AT E497809T1 AT 05750345 T AT05750345 T AT 05750345T AT 05750345 T AT05750345 T AT 05750345T AT E497809 T1 ATE497809 T1 AT E497809T1
- Authority
- AT
- Austria
- Prior art keywords
- myricitrine
- compounds used
- sleep disorders
- treat sleep
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57252804P | 2004-05-18 | 2004-05-18 | |
| PCT/US2005/016783 WO2005115547A2 (en) | 2004-05-18 | 2005-05-13 | Myricitrin compounds for sleeping disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE497809T1 true ATE497809T1 (de) | 2011-02-15 |
Family
ID=34993353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05750345T ATE497809T1 (de) | 2004-05-18 | 2005-05-13 | Myricitrin verbindungen zur behandlung von schlafstörungen |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7935714B2 (de) |
| EP (1) | EP1750808B1 (de) |
| JP (1) | JP2007538078A (de) |
| KR (1) | KR20070020036A (de) |
| CN (1) | CN101001670B (de) |
| AT (1) | ATE497809T1 (de) |
| DE (1) | DE602005026276D1 (de) |
| WO (1) | WO2005115547A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006222556B2 (en) * | 2005-03-11 | 2011-09-29 | Armaron Bio Pty Ltd | Flavonoid compounds and uses thereof |
| US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| GB0618168D0 (en) * | 2006-09-15 | 2006-10-25 | Babraham Inst | Compounds |
| TWI366565B (en) * | 2007-06-06 | 2012-06-21 | Otsuka Pharma Co Ltd | Quinolone compound and pharmaceutical composition |
| JP5247667B2 (ja) * | 2008-12-05 | 2013-07-24 | 大塚製薬株式会社 | 医薬 |
| WO2013051727A1 (ja) * | 2011-10-06 | 2013-04-11 | ライオン株式会社 | 睡眠の質改善剤 |
| CN103381152A (zh) * | 2013-02-05 | 2013-11-06 | 吉林省金梓源生物科技有限公司 | 杨梅素作为组织蛋白酶k抑制剂的用途 |
| EP3218721B1 (de) * | 2014-11-14 | 2021-08-18 | United Arab Emirates University | Verbindungen zur verwendung als kontrastmittel |
| CN105712966B (zh) * | 2016-01-22 | 2018-06-12 | 梁京 | 一种苯酚茶酸素及其制备方法和应用 |
| CN106674216B (zh) * | 2016-12-21 | 2019-06-11 | 贵州大学 | 一种含噻二唑硫醚结构的杨梅素衍生物及其制备方法 |
| CN107137391A (zh) * | 2017-05-23 | 2017-09-08 | 苏州大学 | 二氢杨梅素在制备治疗抑郁症的药物方面的用途 |
| CN110063952A (zh) * | 2018-01-22 | 2019-07-30 | 山东冠秀生物科技有限公司 | 二氢杨梅素衍生物在治疗改善睡眠中的用途 |
| EP3643183A1 (de) * | 2018-10-26 | 2020-04-29 | Analyticon Discovery GmbH | Zubereitungen mit c-methylflavonoiden |
| JP7392219B2 (ja) * | 2020-01-20 | 2023-12-06 | 株式会社萌芽プランツ | フラボノイド組成物 |
| US12194021B2 (en) | 2021-05-24 | 2025-01-14 | University Of Southern California | Modified herbal compositions for neuromodulation |
| PT4426434T (pt) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Agonistas inversos de pparg e suas utilizações |
| CN116514788B (zh) * | 2023-04-10 | 2025-05-13 | 贵州医科大学 | 一种色原酮类mTOR抑制剂及其药物组合物和应用 |
| CN117582449B (zh) * | 2024-01-18 | 2025-03-11 | 北京佳福瑞生物科技有限公司 | 一种基于smarto-one技术的具有神经系统调节作用的复合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5502047A (en) | 1993-03-22 | 1996-03-26 | Kavey; Neil B. | Treatment for insomnia |
| JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
| JPH0987619A (ja) * | 1995-09-28 | 1997-03-31 | Sanei Gen F F I Inc | 酸化防止剤の製造法 |
| US6224872B1 (en) * | 1997-07-31 | 2001-05-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Composition |
| US20030206895A1 (en) * | 1998-11-13 | 2003-11-06 | Sigma-Tau Healthscience S.P.A. | Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis |
| IT1306722B1 (it) | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di |
| US6211229B1 (en) | 2000-02-17 | 2001-04-03 | Neil B. Kavey | Treatment of transient and short term insomnia |
| EP1127572A3 (de) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Verwendung von Flavonen zur Behandlung von Cyclooxygenase-2 ermittelten Krankheiten |
| US6344487B1 (en) | 2000-06-05 | 2002-02-05 | Neil B. Kavey | Treatment of insomnia |
| KR100407399B1 (ko) * | 2000-08-22 | 2003-11-28 | 주식회사 뉴로넥스 | 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제 |
| BR0204228A (pt) * | 2001-02-20 | 2004-06-22 | Randy Ziegler | Métodos para melhorar os sintomas de uma psicose e de esquizofrenia e para triar moléculas de teste, e, composto orgânico |
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
-
2005
- 2005-05-13 CN CN2005800158156A patent/CN101001670B/zh not_active Expired - Lifetime
- 2005-05-13 US US11/129,628 patent/US7935714B2/en active Active
- 2005-05-13 EP EP05750345A patent/EP1750808B1/de not_active Expired - Lifetime
- 2005-05-13 JP JP2007527316A patent/JP2007538078A/ja active Pending
- 2005-05-13 KR KR1020067024012A patent/KR20070020036A/ko not_active Ceased
- 2005-05-13 DE DE602005026276T patent/DE602005026276D1/de not_active Expired - Lifetime
- 2005-05-13 AT AT05750345T patent/ATE497809T1/de not_active IP Right Cessation
- 2005-05-13 WO PCT/US2005/016783 patent/WO2005115547A2/en not_active Ceased
-
2008
- 2008-12-19 US US12/340,376 patent/US20090124627A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101001670A (zh) | 2007-07-18 |
| KR20070020036A (ko) | 2007-02-16 |
| EP1750808A2 (de) | 2007-02-14 |
| WO2005115547A2 (en) | 2005-12-08 |
| CN101001670B (zh) | 2012-10-03 |
| DE602005026276D1 (de) | 2011-03-24 |
| US7935714B2 (en) | 2011-05-03 |
| US20050261167A1 (en) | 2005-11-24 |
| JP2007538078A (ja) | 2007-12-27 |
| WO2005115547A3 (en) | 2007-03-08 |
| EP1750808B1 (de) | 2011-02-09 |
| US20090124627A1 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE497809T1 (de) | Myricitrin verbindungen zur behandlung von schlafstörungen | |
| DE502005001828D1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE60025812D1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
| ATE446097T1 (de) | Verwendung von uridin in kombination mit cholin zur behandlung von gedächtnisstörungen | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| DE602005018763D1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| ATE299369T1 (de) | Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE69428791D1 (de) | Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden | |
| ATE305300T1 (de) | Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren | |
| DE60327557D1 (de) | Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie | |
| DE60216495D1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| ATE542542T1 (de) | Verwendung von gp130 aktivatoren zur behandlung von diabetischer neuropathie | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
| EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
| MXPA04011018A (es) | Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias. | |
| TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |